To link to the entire object, paste this link in email, IM or documentTo embed the entire object, paste this HTML in websiteTo link to this page, paste this link in email, IM or documentTo embed this page, paste this HTML in website

Oklahoma Immunization Update
October 2012
PREVENTION and PREPAREDNESS SERVICES
IMMUNIZATION SERVICE
PLEASE POST & DISTRIBUTE TO ALL NURSING AND MEDICAL STAFF
Pentacel® Shortage
The current Pentacel (DTaP-IPV/Hib) vaccine shortage is now expected to intensify and to last through March 2013. While there will continue to be sufficient DTaP-containing vaccines available to ensure all children can receive the five-dose series of DTaP, current Pentacel allocations for state Vaccines for Children (VFC) Programs will decrease significantly beginning this month. State VFC programs’ allocations of Pentacel will be reduced by 80%. This is a further reduction to the cuts states have had since the shortage began in May 2012. Sanofi Pasteur is also maintaining order restrictions on their private orders for both Pentacel and DTaP vaccines. Based on the combined supply of DTaP-containing vaccines produced by both Sanofi and GlaxoSmithKline (GSK), the Centers for Disease Control and Prevention (CDC) is not planning allocations for DTaP products at this time. CDC will not be allocating Sanofi Pasteur’s IPV or Hib vaccines. Many vaccines are available to use to assure that children are vaccinated on time. Providers can use other combination or individual antigen products: DTaP-IPV-HepB (Pediarix®-GSK) DTaP (Infanrix®-GSK) or (Daptacel-Sanofi Pasteur) IPV (Ipol®-Sanofi Pasteur) Hib (PedvaxHIB®-Merck) or (ActHIB®-Sanofi Pasteur) See sample schedules using single component and combination vaccines in “Guidance for Vaccinating Children during the 2012 Pentacel® and Daptacel® Shortage.” This document is available on the Immunization Service webpage, Information for Health Professionals section at: http://www.ok.gov/health/Disease,_Prevention,_Preparedness/Immunizations/Information_for_Health_Professionals/index.html. VFC providers should consult their Immunization Field Consultant or Regional Immunization Coordinator as needed to adjust ordering levels for these vaccines.
Use of PCV13 in Adults with Immunocompromising Conditions
The Advisory Committee on Immunization Practices (ACIP) has issued provisional recommendations for the use of 13-valent Pneumococcal Conjugate Vaccine (PCV13) in adults 19 years of age and older with
immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid (CSF) leaks, or cochlear implants . PCV13 should be administered to eligible adults in addition to the 23-valent pneumococcal polysaccharide vaccine (PPSV23 - Pneumovax®), the vaccine recommended for this group of adults since 1997. The recommendations are available at:
http://www.cdc.gov/vaccines/recs/provisional/downloads/pcv13-adults-ic.pdf.
Do Current Rotavirus Vaccines Cause Intussception?
A University of Michigan study published in the January 2, 2012, issue of Archives of Pediatric & Adolescent Medicine, shows the re-introduction of rotavirus vaccine has not caused an increase in intussusception. “The investigators examined data trends from the decade prior to vaccine re-introduction, 1997-2006, and then made comparisons to data after vaccine re-introduction.
When comparing data, investigators expected to see 36 intussusception-related hospitalizations per 100,000 children under 1-year-old by 2009. Despite the re-introduction of the vaccines, there were only 33.3 hospitalizations per 100,000 children in 2009, making it very unlikely that the vaccines led to additional cases.”
“We hope that our study provides information that will continue to reassure parents that the benefits of rotavirus vaccine outweigh the risks,” says Zickafoose, lead author of the study.
This information was obtained from materials provided by the University of Michigan Health System accessed on October 1, 2012 at: http://www.uofmhealth.org/news/zickafoose-rotavirus-0102. The study cited is “Hospitalizations for Intussusception Before and After the Reintroduction of Rotavirus Vaccine in the United States,” (Zickafoose SJ, Benneyworth BD, Riebschleger MP, et al. 2012 Jan 2).
Congratulations to Anadarko Indian Health Center!
The Public Health Service Anadarko Indian Health Center increased the immunization rate of children 24 months of age from 67% in 2010 to 92% as of 9-28-2012 for the primary series of vaccines (4 DTaP, 3 polio, 1 MMR, 3 Hib, 3 HepB, and 1 varicella.) To reach this high level, the staff offered vaccines at every visit that the patient made to the clinic, not just immunization visits. The staff also made sure that patient’s records were up-to-date in Oklahoma’s State Immunization Information System (OSIIS). The Immunization Service appreciates the commitment and effort of the staff of the Anadarko Indian Health Center in reaching this level.
For an online version of this Update, visit the Immunization Service web page at: http://www.ok.gov/health/Disease,_Prevention,_Preparedness/Immunizations/Information_for_Health_Professionals/index.html.
If you have any questions about this material, contact the Immunization Service by telephone at 405.271.4073 or by e-mail at immunize@health.ok.gov.

Oklahoma Immunization Update
October 2012
PREVENTION and PREPAREDNESS SERVICES
IMMUNIZATION SERVICE
PLEASE POST & DISTRIBUTE TO ALL NURSING AND MEDICAL STAFF
Pentacel® Shortage
The current Pentacel (DTaP-IPV/Hib) vaccine shortage is now expected to intensify and to last through March 2013. While there will continue to be sufficient DTaP-containing vaccines available to ensure all children can receive the five-dose series of DTaP, current Pentacel allocations for state Vaccines for Children (VFC) Programs will decrease significantly beginning this month. State VFC programs’ allocations of Pentacel will be reduced by 80%. This is a further reduction to the cuts states have had since the shortage began in May 2012. Sanofi Pasteur is also maintaining order restrictions on their private orders for both Pentacel and DTaP vaccines. Based on the combined supply of DTaP-containing vaccines produced by both Sanofi and GlaxoSmithKline (GSK), the Centers for Disease Control and Prevention (CDC) is not planning allocations for DTaP products at this time. CDC will not be allocating Sanofi Pasteur’s IPV or Hib vaccines. Many vaccines are available to use to assure that children are vaccinated on time. Providers can use other combination or individual antigen products: DTaP-IPV-HepB (Pediarix®-GSK) DTaP (Infanrix®-GSK) or (Daptacel-Sanofi Pasteur) IPV (Ipol®-Sanofi Pasteur) Hib (PedvaxHIB®-Merck) or (ActHIB®-Sanofi Pasteur) See sample schedules using single component and combination vaccines in “Guidance for Vaccinating Children during the 2012 Pentacel® and Daptacel® Shortage.” This document is available on the Immunization Service webpage, Information for Health Professionals section at: http://www.ok.gov/health/Disease,_Prevention,_Preparedness/Immunizations/Information_for_Health_Professionals/index.html. VFC providers should consult their Immunization Field Consultant or Regional Immunization Coordinator as needed to adjust ordering levels for these vaccines.
Use of PCV13 in Adults with Immunocompromising Conditions
The Advisory Committee on Immunization Practices (ACIP) has issued provisional recommendations for the use of 13-valent Pneumococcal Conjugate Vaccine (PCV13) in adults 19 years of age and older with
immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid (CSF) leaks, or cochlear implants . PCV13 should be administered to eligible adults in addition to the 23-valent pneumococcal polysaccharide vaccine (PPSV23 - Pneumovax®), the vaccine recommended for this group of adults since 1997. The recommendations are available at:
http://www.cdc.gov/vaccines/recs/provisional/downloads/pcv13-adults-ic.pdf.
Do Current Rotavirus Vaccines Cause Intussception?
A University of Michigan study published in the January 2, 2012, issue of Archives of Pediatric & Adolescent Medicine, shows the re-introduction of rotavirus vaccine has not caused an increase in intussusception. “The investigators examined data trends from the decade prior to vaccine re-introduction, 1997-2006, and then made comparisons to data after vaccine re-introduction.
When comparing data, investigators expected to see 36 intussusception-related hospitalizations per 100,000 children under 1-year-old by 2009. Despite the re-introduction of the vaccines, there were only 33.3 hospitalizations per 100,000 children in 2009, making it very unlikely that the vaccines led to additional cases.”
“We hope that our study provides information that will continue to reassure parents that the benefits of rotavirus vaccine outweigh the risks,” says Zickafoose, lead author of the study.
This information was obtained from materials provided by the University of Michigan Health System accessed on October 1, 2012 at: http://www.uofmhealth.org/news/zickafoose-rotavirus-0102. The study cited is “Hospitalizations for Intussusception Before and After the Reintroduction of Rotavirus Vaccine in the United States,” (Zickafoose SJ, Benneyworth BD, Riebschleger MP, et al. 2012 Jan 2).
Congratulations to Anadarko Indian Health Center!
The Public Health Service Anadarko Indian Health Center increased the immunization rate of children 24 months of age from 67% in 2010 to 92% as of 9-28-2012 for the primary series of vaccines (4 DTaP, 3 polio, 1 MMR, 3 Hib, 3 HepB, and 1 varicella.) To reach this high level, the staff offered vaccines at every visit that the patient made to the clinic, not just immunization visits. The staff also made sure that patient’s records were up-to-date in Oklahoma’s State Immunization Information System (OSIIS). The Immunization Service appreciates the commitment and effort of the staff of the Anadarko Indian Health Center in reaching this level.
For an online version of this Update, visit the Immunization Service web page at: http://www.ok.gov/health/Disease,_Prevention,_Preparedness/Immunizations/Information_for_Health_Professionals/index.html.
If you have any questions about this material, contact the Immunization Service by telephone at 405.271.4073 or by e-mail at immunize@health.ok.gov.